VibroniX Secures Nearly CNY 100 Million in Series A+ Funding

Technology Author: EqualOcean News Jun 24, 2024 06:05 PM (GMT+8)

EqualOcean reports that on June 24, 2024, Suzhou VibroniX Photonics Technology Co., Ltd. (hereinafter referred to as "VibroniX") announced the completion of a Series A+ funding round, raising nearly CNY 100 million.

Medical health

The round was led by Tao Capital(道远资本), with additional investments from existing investor Frees Fund(峰瑞资本) and follow-up investment from Founder H Fund(方正和生). The funds will be used to accelerate the commercialization of VibroniX's spectroscopic analysis products, iterate industrial solutions, and develop applications for multiplex immunohistochemistry.

Founded in 2017, VibroniX focuses on molecular vibration spectroscopy innovation, aiming to develop high-end domestic spectroscopic analysis and imaging products, as well as precision medical diagnostic platforms. The company has received accolades such as National High-Tech Enterprise qualification, Suzhou Industrial Park Science and Technology Leading Talent title, and second prize in the China Medical Device Innovation and Entrepreneurship Competition. The core team has extensive research and development experience in spectroscopy, optical imaging, and photoelectric analysis, holding over 10 self-developed core patents and 16 exclusive patents authorized by world-renowned research institutions.

VibroniX boasts over 1,000 square meters of R&D and production space, a comprehensive design and development system, and quality control systems certified for medical device quality and GMP. The core team possesses expertise in complex optical path design and ultra-sensitive optomechanical detection technology, establishing a fast, sensitive, high-throughput spectroscopic analysis and imaging technology platform with the potential to replace existing solutions and explore new application scenarios.

The company has developed three main spectroscopic technology platforms: Coherent Raman, Transient Absorption, and Ultrafast Laser Infrared. These platforms significantly enhance the specificity, sensitivity, resolution, and imaging speed of spectroscopic analysis. The Coherent Raman platform increases sensitivity by 106 times compared to spontaneous Raman, with imaging resolution reaching 200-500 nm and the ability to perform chemically specific, non-destructive, label-free imaging. The Ultrafast Laser Infrared platform offers high resolution, rapid imaging, high sensitivity, and excellent signal-to-noise ratio with water background suppression. The Transient Absorption platform features ultra-high sensitivity (up to 10^-7 OD with 100 μs integration time) and fast imaging speeds (up to 10 FPS), leading the industry.

In terms of commercialization, VibroniX's engineered products address analysis and imaging needs in various fields, including life sciences (metabolic research, cancer research, multiplex immunohistochemistry, drug analysis), synthetic biology research and production quality control, materials science (graphene, organic optoelectronic materials, microcrystals, silicon carbide), and environmental science (environmental monitoring, microplastic analysis). The company provides superior domestic analysis and imaging tools for research institutions, industrial monitoring, and medical testing, gaining broad recognition and achieving rapid sales growth.